GlobeNewswire Inc | Apr 8, 2021 07:30AM EDT

April 08, 2021

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 3:00 p.m. ET.

A live webcast of the fireside chat will be available on the investor section of the companys website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The companys non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is engineered to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The companys efficient, scalable manufacturing process supports Generation Bios mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.

For more information, please visitwww.generationbio.com.

Contact:

InvestorsMaren KillackeyGeneration Biomkillackey@generationbio.com541-646-2420

MediaAlicia WebbGeneration Bioawebb@generationbio.com847-254-4275

Stephanie SimonTenBridge Communicationsstephanie@tenbridgecommunications.com617-581-9333